PCSA executive buys 1,369 Processa shares

Processa Pharmaceuticals, Inc. Chief Business - Strategy Officer Patrick Lin reported an open-market purchase of 1,369 shares of common stock at $2.97 per share.

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Business - Strategy Officer Patrick Lin reported an open-market purchase of 1,369 shares of common stock at $2.97 per share. Following this transaction, he directly owns 7,594 shares and indirectly holds 1,740 shares through the Lin Family Trust dated February 4, 2024.

A footnote states that share figures were adjusted to correct immaterial errors in a prior Form 4. The corrected price per share for a purchase on April 30, 2026 is $2.71 instead of $2.69, which reduced that earlier purchase by 11 shares.

Insider Trade Summary

Net Buyer: 1,369 shares

Net Buy 2 txns

Insider Lin Patrick

Role Chief Business - Strategy Off

Bought 1,369 shs ($4K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,369	$2.97	$4K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 7,594 shares (Direct); Common Stock — 1,740 shares (Indirect, Lin Family Trust Feb 4, 2024)

Footnotes (1)

1. F1. Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 11 shares.

Key Figures

Open-market purchase: 1,369 shares at $2.97 Direct holdings after trade: 7,594 shares Indirect trust holdings: 1,740 shares +3 more

6 metrics

Open-market purchase 1,369 shares at $2.97 Common Stock transaction on May 15, 2026

Direct holdings after trade 7,594 shares Common Stock directly owned after May 15, 2026 transaction

Indirect trust holdings 1,740 shares Common Stock held via Lin Family Trust Feb 4, 2024

Corrected prior purchase price $2.71 per share April 30, 2026 purchase, previously reported as $2.69

Share reduction from correction 11 shares Adjustment to April 30, 2026 prior purchase

Net share change in filing 1,369 shares net buy transactionSummary netBuySellShares

Key Terms

open-market purchase, Form 4, indirect ownership, Lin Family Trust Feb 4, 2024

4 terms

open-market purchase financial

"The transaction is described as an open-market purchase of 1,369 shares at $2.97 per share."

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Form 4 regulatory

"Errors were corrected from the Form 4 filed on May 1, 2026, including price and share count."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

indirect ownership financial

"1,740 shares are reported as indirectly owned through the Lin Family Trust dated February 4, 2024."

Lin Family Trust Feb 4, 2024 financial

"Common Stock is held indirectly with nature of ownership listed as Lin Family Trust Feb 4, 2024."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PCSA executive Patrick Lin report on this Form 4?

Patrick Lin reported buying 1,369 PCSA shares. He completed an open-market purchase of 1,369 shares of Processa Pharmaceuticals common stock at $2.97 per share, increasing his directly owned position as disclosed in the Form 4 filing.

How many Processa Pharmaceuticals (PCSA) shares does Patrick Lin own after this transaction?

After the transaction, Patrick Lin holds 7,594 direct PCSA shares. The Form 4 also shows 1,740 additional shares held indirectly through the Lin Family Trust dated February 4, 2024, giving context for his total reported ownership.

What was the purchase price for Patrick Lin’s recent PCSA share acquisition?

Patrick Lin bought the new PCSA shares at $2.97 each. The Form 4 identifies the transaction as an open-market purchase of 1,369 common shares, specifying a transaction price per share of $2.97.

What correction does the footnote in Patrick Lin’s PCSA Form 4 explain?

The footnote corrects an earlier Form 4 entry. It states the April 30, 2026 purchase price should be $2.71 instead of $2.69, which reduces that prior purchase amount by 11 shares, described as an immaterial error.

How many PCSA shares are held indirectly for Patrick Lin through a trust?

Patrick Lin is reported with 1,740 indirectly held PCSA shares. The Form 4 lists these common shares as indirectly owned through the Lin Family Trust dated February 4, 2024, separate from his directly owned 7,594 shares.

Does this PCSA Form 4 include any derivative securities for Patrick Lin?

The filing shows no derivative securities for Patrick Lin. The derivative section is empty in this Form 4, indicating no reported options, warrants, or other derivative positions associated with this particular disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 06:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Patrick

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business - Strategy Off

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		P		1,369	A	$2.97	7,594(1)	D
Common Stock								1,740	I	Lin Family Trust Feb 4, 2024

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 11 shares.

	/s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)